Updated:
Global Neurohealth Ventures
Global Neurohealth Ventures invests in early-stage neurohealth companies, backing brain-computer interfaces and digital therapeutics from a San Francisco...
Global Neurohealth Ventures
Global Neurohealth Ventures operates as a private equity firm targeting early-stage neurohealth opportunities. Founded with a focus on neuroscience-focused innovation, the firm provides capital to companies developing brain-computer interfaces, digital biomarkers, and novel therapeutics for conditions like Alzheimer's, depression, and traumatic brain injury (public record). The firm's strategy spans seed through Series A rounds across digital health, AI/ML, and advanced diagnostics. Confirmed portfolio companies include neurotech startups such as Neurable, a brain-computer interface developer, and Mindstrong, a digital mental health platform using smartphone data for depression monitoring (per public record, 2023). Investment geography centers on North America, with company bases in the Bay Area and Boston. Global Neurohealth Ventures lists no public AUM, team size, or office locations beyond San Francisco. No additional funding vehicles or philanthropic arms have been disclosed. The firm's operational history is lightly documented in public sources, limiting visibility into scale and deal volume. The structural differentiator is its exclusive focus on neurohealth — an asset class that spans biotech, software, and medical devices. This concentration provides domain expertise but narrows the addressable deal flow relative to generalist healthcare funds.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Global Neurohealth Ventures?
The firm does not publicly disclose its investment committee or managing partners. Based on its structure as a private equity firm, decisions are likely made by a small team of general partners, though individual names are not available in public sources.
How does Global Neurohealth Ventures source proprietary deal flow?
The firm likely leverages relationships within academic neuroscience centers, medical schools, and neurotech accelerators. Its narrow focus on neurohealth may provide access to pre-commercial technologies that generalist funds overlook, though specific sourcing methods are not publicly documented.
Is Global Neurohealth Ventures structured as a single family office or does it operate more like a venture firm?
The firm identifies as an asset manager and private equity firm, which suggests a fund-based structure typical of venture capital. However, the lack of public AUM or vehicle details leaves the exact legal structure unconfirmed — it could operate as a fund, a family office, or a combination.
Does Global Neurohealth Ventures participate in fund commitments or only direct deals?
Public sources indicate the firm makes direct investments in early-stage neurohealth companies, primarily at seed and Series A. There is no evidence of fund-of-funds or secondary commitments, but the firm's full mandate is not publicly detailed.
What investment stages does Global Neurohealth Ventures typically target?
The firm targets early-stage venture rounds, specifically seed and Series A. Its focus on neurohealth startups with long development timelines suggests comfort with pre-revenue, research-stage companies that require significant technical diligence.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: